Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9701 |
High Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.9235 |
High Similarity |
NPD6797 |
Phase 2 |
0.9181 |
High Similarity |
NPD7251 |
Discontinued |
0.9128 |
High Similarity |
NPD7808 |
Phase 3 |
0.9064 |
High Similarity |
NPD7472 |
Approved |
0.9006 |
High Similarity |
NPD7054 |
Approved |
0.8947 |
High Similarity |
NPD3818 |
Discontinued |
0.8844 |
High Similarity |
NPD7074 |
Phase 3 |
0.8698 |
High Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.869 |
High Similarity |
NPD3817 |
Phase 2 |
0.8631 |
High Similarity |
NPD2801 |
Approved |
0.8613 |
High Similarity |
NPD6166 |
Phase 2 |
0.8613 |
High Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.8613 |
High Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.858 |
High Similarity |
NPD5402 |
Approved |
0.8571 |
High Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.8462 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8421 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.8421 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.8371 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.8323 |
Intermediate Similarity |
NPD1512 |
Approved |
0.8304 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8266 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.8225 |
Intermediate Similarity |
NPD1653 |
Approved |
0.8204 |
Intermediate Similarity |
NPD1511 |
Approved |
0.8166 |
Intermediate Similarity |
NPD5403 |
Approved |
0.814 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.8129 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.8118 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.8092 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.8047 |
Intermediate Similarity |
NPD5401 |
Approved |
0.8022 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7988 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7966 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7956 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7901 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7886 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7877 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7836 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7826 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7778 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7765 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7754 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7747 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7742 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7742 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7738 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7738 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7735 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7725 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7714 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7705 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7704 |
Intermediate Similarity |
NPD7435 |
Discontinued |
0.7692 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7684 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.767 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7644 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7624 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7624 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7611 |
Intermediate Similarity |
NPD919 |
Approved |
0.7611 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7551 |
Intermediate Similarity |
NPD6777 |
Approved |
0.7551 |
Intermediate Similarity |
NPD6776 |
Approved |
0.7551 |
Intermediate Similarity |
NPD6780 |
Approved |
0.7551 |
Intermediate Similarity |
NPD6778 |
Approved |
0.7551 |
Intermediate Similarity |
NPD6779 |
Approved |
0.7551 |
Intermediate Similarity |
NPD6781 |
Approved |
0.7551 |
Intermediate Similarity |
NPD6782 |
Approved |
0.7542 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7528 |
Intermediate Similarity |
NPD37 |
Approved |
0.7515 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD4966 |
Approved |
0.75 |
Intermediate Similarity |
NPD4965 |
Approved |
0.75 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7475 |
Intermediate Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.7475 |
Intermediate Similarity |
NPD7874 |
Approved |
0.7471 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7432 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7429 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7427 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7426 |
Intermediate Similarity |
NPD8151 |
Discontinued |
0.7405 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7399 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7398 |
Intermediate Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.7389 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7384 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7381 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7381 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7371 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7363 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7354 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7353 |
Intermediate Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.7353 |
Intermediate Similarity |
NPD7783 |
Phase 2 |
0.7351 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.735 |
Intermediate Similarity |
NPD7697 |
Approved |
0.735 |
Intermediate Similarity |
NPD7696 |
Phase 3 |
0.735 |
Intermediate Similarity |
NPD7698 |
Approved |
0.7337 |
Intermediate Similarity |
NPD1933 |
Approved |
0.7337 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7313 |
Intermediate Similarity |
NPD7870 |
Phase 2 |
0.7313 |
Intermediate Similarity |
NPD7871 |
Phase 2 |
0.7296 |
Intermediate Similarity |
NPD6535 |
Approved |
0.7296 |
Intermediate Similarity |
NPD6534 |
Approved |
0.7291 |
Intermediate Similarity |
NPD7701 |
Phase 2 |
0.7278 |
Intermediate Similarity |
NPD943 |
Approved |
0.7267 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7267 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7254 |
Intermediate Similarity |
NPD8434 |
Phase 2 |
0.7241 |
Intermediate Similarity |
NPD7584 |
Approved |
0.7235 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7213 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7211 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.72 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7186 |
Intermediate Similarity |
NPD7700 |
Phase 2 |
0.7186 |
Intermediate Similarity |
NPD7699 |
Phase 2 |
0.7184 |
Intermediate Similarity |
NPD7801 |
Approved |
0.7176 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7165 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.716 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD8320 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD8319 |
Approved |
0.7143 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7135 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7135 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7135 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7129 |
Intermediate Similarity |
NPD6823 |
Phase 2 |
0.7123 |
Intermediate Similarity |
NPD8155 |
Clinical (unspecified phase) |
0.7118 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.711 |
Intermediate Similarity |
NPD3748 |
Approved |
0.711 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.7101 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7093 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7083 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7056 |
Intermediate Similarity |
NPD920 |
Approved |
0.7045 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7039 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7039 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7039 |
Intermediate Similarity |
NPD7585 |
Approved |
0.7037 |
Intermediate Similarity |
NPD7784 |
Clinical (unspecified phase) |
0.7024 |
Intermediate Similarity |
NPD7211 |
Clinical (unspecified phase) |
0.7016 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.701 |
Intermediate Similarity |
NPD7680 |
Approved |
0.699 |
Remote Similarity |
NPD7583 |
Approved |
0.698 |
Remote Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.6978 |
Remote Similarity |
NPD3226 |
Approved |
0.6977 |
Remote Similarity |
NPD5619 |
Clinical (unspecified phase) |
0.6959 |
Remote Similarity |
NPD6798 |
Discontinued |
0.6959 |
Remote Similarity |
NPD2313 |
Discontinued |
0.6957 |
Remote Similarity |
NPD6844 |
Discontinued |
0.6949 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6946 |
Remote Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.6927 |
Remote Similarity |
NPD643 |
Clinical (unspecified phase) |
0.6919 |
Remote Similarity |
NPD4062 |
Phase 3 |
0.6914 |
Remote Similarity |
NPD7033 |
Discontinued |
0.69 |
Remote Similarity |
NPD6214 |
Clinical (unspecified phase) |
0.69 |
Remote Similarity |
NPD6212 |
Phase 3 |
0.69 |
Remote Similarity |
NPD6213 |
Phase 3 |
0.6885 |
Remote Similarity |
NPD7458 |
Discontinued |
0.6882 |
Remote Similarity |
NPD5353 |
Approved |
0.6864 |
Remote Similarity |
NPD1203 |
Approved |
0.6854 |
Remote Similarity |
NPD2800 |
Approved |
0.6854 |
Remote Similarity |
NPD1243 |
Approved |
0.6842 |
Remote Similarity |
NPD6832 |
Phase 2 |
0.6839 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6836 |
Remote Similarity |
NPD2346 |
Discontinued |
0.6826 |
Remote Similarity |
NPD1091 |
Approved |
0.6818 |
Remote Similarity |
NPD2799 |
Discontinued |
0.6806 |
Remote Similarity |
NPD5242 |
Approved |
0.6796 |
Remote Similarity |
NPD5006 |
Approved |
0.6796 |
Remote Similarity |
NPD5005 |
Approved |
0.6793 |
Remote Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.6786 |
Remote Similarity |
NPD7549 |
Discontinued |
0.6786 |
Remote Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.6786 |
Remote Similarity |
NPD9269 |
Phase 2 |
0.6784 |
Remote Similarity |
NPD9494 |
Approved |
0.6782 |
Remote Similarity |
NPD4360 |
Phase 2 |
0.6782 |
Remote Similarity |
NPD4363 |
Phase 3 |
0.676 |
Remote Similarity |
NPD6674 |
Discontinued |
0.6754 |
Remote Similarity |
NPD5711 |
Approved |
0.6754 |
Remote Similarity |
NPD5710 |
Approved |
0.6754 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.6743 |
Remote Similarity |
NPD4340 |
Discontinued |
0.6743 |
Remote Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.6743 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6743 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6722 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.672 |
Remote Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.672 |
Remote Similarity |
NPD6386 |
Approved |
0.672 |
Remote Similarity |
NPD6385 |
Approved |
0.6717 |
Remote Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.6706 |
Remote Similarity |
NPD3225 |
Approved |
0.6702 |
Remote Similarity |
NPD8127 |
Discontinued |
0.6686 |
Remote Similarity |
NPD4060 |
Phase 1 |
0.6685 |
Remote Similarity |
NPD6099 |
Approved |
0.6685 |
Remote Similarity |
NPD6100 |
Approved |
0.6683 |
Remote Similarity |
NPD4420 |
Approved |
0.6682 |
Remote Similarity |
NPD7930 |
Approved |
0.6667 |
Remote Similarity |
NPD1296 |
Phase 2 |
0.6667
|
Remote Similarity |
NPD3268 |
Approved |